ARS Pharmaceuticals, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
ARS Pharmaceuticals, Inc. (SPRY) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 20.62 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 20.43M shares, a 16.98% increase year-over-year.
- ARS Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 17.46M shares, a 20.64% increase year-over-year.
- ARS Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 14.47M shares, a 7.50% decline year-over-year.
- ARS Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 15.65M shares, a 50.94% decline year-over-year.
- ARS Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 16.79M shares, a 167.98% increase from fiscal 2024.
- ARS Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 6.27M shares, a 45.72% decline from fiscal 2023.
- ARS Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 11.54M shares, a 4.76% decline from fiscal 2022.
- ARS Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 12.12M shares, a 61.27% decline from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 20.62M shares 10-Q · filed 2026-08-13 | |||||||
| 2026-03-31 | 20.43M shares 10-Q · filed 2026-05-15 | |||||||
| 2025-12-31 | 16.79M shares 10-K · filed 2026-03-09 | |||||||
| 2025-09-30 | 17.20M shares 10-Q · filed 2025-11-10 | |||||||
| 2025-06-30 | 17.32M shares 10-Q · filed 2026-08-13 | |||||||
| 2025-03-31 | 17.46M shares 10-Q · filed 2026-05-15 | |||||||
| 2024-12-31 | 6.27M shares 10-K · filed 2026-03-09 | |||||||
| 2024-09-30 | 15.24M shares 10-Q · filed 2025-11-10 | |||||||
| 2024-06-30 | 14.48M shares 10-Q · filed 2025-08-13 | |||||||
| 2024-03-31 | 14.47M shares 10-Q · filed 2025-05-14 | |||||||
| 2023-12-31 | 11.54M shares 10-K · filed 2025-03-20 | |||||||
| 2023-09-30 | 14.97M shares 10-Q · filed 2024-11-13 | 14.95M shares 10-Q · filed 2023-11-09 | ||||||
| 2023-06-30 | 15.43M shares 10-Q · filed 2024-08-06 | 15.43M shares 10-Q · filed 2023-08-10 | ||||||
| 2023-03-31 | 15.65M shares 10-Q · filed 2024-05-09 | 15.63M shares 10-Q · filed 2023-05-15 | ||||||
| 2022-12-31 | 12.12M shares 10-K · filed 2024-03-21 | 12.11M shares 10-K · filed 2023-03-23 | ||||||
| 2022-09-30 | 32.15M shares 10-Q · filed 2023-11-09 | 7.55M shares 10-Q · filed 2022-11-02 | ||||||
| 2022-06-30 | 32.15M shares 10-Q · filed 2023-08-10 | 9.41M shares 10-Q · filed 2022-08-11 | ||||||
| 2022-03-31 | 31.89M shares 10-Q · filed 2023-05-15 | 8.20M shares 10-Q · filed 2022-05-12 | ||||||
| 2021-12-31 | 31.29M shares 10-K · filed 2023-03-23 | 6.40M shares 10-K · filed 2022-03-31 | ||||||
| 2021-09-30 | 6.50M shares 10-Q · filed 2022-11-02 | |||||||
| 2021-06-30 | 6.50M shares 10-Q · filed 2022-08-11 | |||||||
| 2021-03-31 | 6.40M shares 10-Q · filed 2022-05-12 | |||||||
| 2020-12-31 | 6.42M shares 10-K · filed 2022-03-31 | |||||||
| 2020-09-30 | 23.36M shares 10-Q · filed 2021-11-10 | |||||||
| 2020-06-30 | 10.68M shares 10-Q · filed 2021-08-12 | |||||||
| 2020-03-31 | 8.76M shares 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |